Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 4.64B P/E - EPS this Y 87.50% Ern Qtrly Grth -61.50%
Income 385.71M Forward P/E 13.12 EPS next Y -3.00% 50D Avg Chg -9.00%
Sales 1.51B PEG 0.41 EPS past 5Y 25.67% 200D Avg Chg 1.00%
Dividend N/A Price/Book 3.63 EPS next 5Y 24.80% 52W High Chg -17.00%
Recommedations 2.40 Quick Ratio 2.42 Shares Outstanding 164.67M 52W Low Chg 29.00%
Insider Own 1.31% ROA 8.62% Shares Float 156.26M Beta 0.42
Inst Own 112.37% ROE 30.08% Shares Shorted/Prior 18.62M/17.70M Price 27.95
Gross Margin 83.31% Profit Margin 19.15% Avg. Volume 1,405,774 Target Price 34.92
Oper. Margin 27.53% Earnings Date Jul 24 Volume 2,776,204 Change -2.07%
About Alkermes plc

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Alkermes plc News
03:13 PM Alkermes Stock Jumps Nearly 30% In 3 Months After Hefty Profits
10/12/24 Is Alkermes (ALKS) The Most Undervalued Quality Stock To Buy According To Analysts?
10/11/24 The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
10/11/24 Here's Why Alkermes (ALKS) is a Strong Momentum Stock
10/10/24 Here's Why Alkermes (ALKS) is a Strong Growth Stock
10/09/24 Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
10/02/24 Alkermes (NASDAQ:ALKS) shareholder returns have been favorable, earning 62% in 5 years
09/25/24 Alkermes to Host Investor Event to Review Orexin Portfolio Strategy
09/23/24 Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term
09/23/24 Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024
09/20/24 Here's Why Alkermes (ALKS) is a Strong Value Stock
09/19/24 Alkermes to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Conference
09/13/24 Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards® Program
09/06/24 Why Is Intra-Cellular (ITCI) Down 2.7% Since Last Earnings Report?
09/04/24 Why Is CRISPR Therapeutics (CRSP) Down 7.7% Since Last Earnings Report?
09/04/24 Why Alkermes (ALKS) is a Top Value Stock for the Long-Term
08/30/24 Why Is Qiagen (QGEN) Down 0.3% Since Last Earnings Report?
08/29/24 Incyte (INCY) Up 0.9% Since Last Earnings Report: Can It Continue?
08/28/24 Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
08/23/24 Alkermes (ALKS) Down 0.2% Since Last Earnings Report: Can It Rebound?
ALKS Chatroom

User Image oratocheri Posted - 4 days ago

$ALKS Another interesting potential buy .. any insiders?

User Image DonCorleone77 Posted - 09/23/24

$ALKS Alkermes to present clinical data from its Phase 1b study of ALKS 2680 Alkermes announced plans to present clinical data from its phase 1b study of ALKS 2680 in patients with narcolepsy type 2, NT2, and idiopathic hypersomnia, IH, at the European Sleep Research Society's, ESRS, 27th Congress, Sleep Europe 2024, taking place Sept. 24-27, 2024 in Seville, Spain. ALKS 2680 is the company's novel, investigational, oral, selective orexin 2 receptor, OX2R, agonist in development as a once-daily treatment for narcolepsy, a chronic, neurological disorder characterized by excessive daytime sleepiness. In an oral presentation and corresponding poster presentation, the company will share data from the cohort of patients with NT2 from the phase 1b, proof-of-concept study evaluating single-dose, oral administration of ALKS 2680. Additionally, the company will present a poster with data from the cohort of patients with IH from the same study. As previously announced, ALKS 2680 was generally well tolerated with improved wakefulness compared to placebo in both cohorts.

User Image Stock_Titan Posted - 09/23/24

$ALKS Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024 https://www.stocktitan.net/news/ALKS/alkermes-to-present-positive-clinical-data-from-phase-1b-study-of-0c3cbscbdhtq.html

User Image harmongreg Posted - 09/22/24

Dragonfly Capital - 5 Trade Ideas for Monday: Alkermes, Citigroup, Caterpillar, Neogen and EchoStar https://dragonflycap.com/5-trade-ideas-for-monday-alkermes-citigroup-caterpillar-neogen-and-echostar/ $ALKS $C $CAT $NEOG $SATS

User Image Stock_Titan Posted - 1 month ago

$ALKS Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards® Program https://www.stocktitan.net/news/ALKS/alkermes-announces-launch-of-7th-annual-alkermes-pathways-research-mibq66iuvi2v.html

User Image k_rma Posted - 1 month ago

$PSIL $MNMD $CMPS $ALKS Hopefully the catalyst the field of psychedelics needs. US gov’t grant for clinical trial on psychedelic treatment of PTSD, traumatic brain injury. submission deadline: 10/4/24

User Image StockInvest_us Posted - 1 month ago

Signal alert: $ALKS - Overbought Trend Short (Overvalued) https://stockinvest.us/l/vU1KaZnmwP

User Image insidemoney Posted - 08/27/24

$ALKS Alkermes 14-Day RSI: 60.3 % from 52-Week Low: +27.0% % from 52-Week High: -15.0% Open Interest: 4,681 % Change: +51% Put/Call Ratio: 1.12 % Change: -40.0%

User Image insidemoney Posted - 08/23/24

Options Spikes (Aug 22) $ALKS Alkermes % Change -1.00% Trade Count 121 Total Notional 114.1 K 90 Day Average 18.6 K Calls 113.4 K Puts 675 $GNTX Gentex % Change -0.20% Trade Count 84 Total Notional 124.5 K 90 Day Average 20.6 K Calls 118.5 K Puts 6 K

User Image Stock_Titan Posted - 08/22/24

$ALKS Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2 https://www.stocktitan.net/news/ALKS/alkermes-announces-initiation-of-vibrance-2-phase-2-study-evaluating-bez7uilty6ld.html

User Image RiskVsReward Posted - 08/20/24

$ALKS Look at this chart! 🏆

User Image contangoz Posted - 08/20/24

BLOOMY upbeat on deal $alks

User Image Shlobby Posted - 08/19/24

$ALKS if you get stopped out once cut and try again. Big candle today

User Image kinderspiel Posted - 08/19/24

today $FULC announced the appointment of isabel kalofonos as CCO & heather faulds as chief regulatory affairs & quality assurance officer. together, they will be instrumental in advancing losmapimod towards a new drug application submission & preparing for commercial launch. ms. kalofonos joins fulcrum from $IMGN where she served as senior vice president & chief commercial officer. most recently, ms. faulds served as svp, regulatory affairs at $ALKS

User Image Fullratio Posted - 08/18/24

Healthcare sector stocks with high YoY EPS growth in Q2 2024: $JNJ $ALKS $NVS

User Image kinderspiel Posted - 08/15/24

Aug 15 highest volume of shares traded $EXAS 410.6 k $NTRA 242.7 k $BEAM 158.6 k $ALKS 120.7 k $BPMC 101.0 k

User Image StockInvest_us Posted - 2 months ago

Signal alert: $ALKS - Overbought Trend Short (Overvalued) https://stockinvest.us/l/JYHI4J7oTn

User Image NVDAMillionaire Posted - 07/31/24

$ALKS Alkermes (ALKS): A Diversified Biopharma Poised for Continued Growth http://beyondspx.com/2024/07/31/alkermes-alks-a-diversified-biopharma-poised-for-continued-growth/

User Image Stocksrunner Posted - 07/28/24

$ALKS Alkermes is in the spotlight after its post-earnings bump, with analysts deeming the stock fairly valued. https://stocksrunner.com/symbol/ALKS

User Image Aigner_Andreas Posted - 07/26/24

TD SELL $ALKS at 25.52, Supp 23.01 Resis 28.04 R22 HiLo 34% T1Y 31 buy 2.5 fwdPE 26.6 DIV N/A #Alkermes p #stocks #trading #finance #market

User Image PenkeTrading Posted - 07/25/24

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Alkermes Plc. Is that bullish or bearish? $ALKS #ALKS #nasdaq #tradingsignals #technicalanalysis

User Image Stocksrunner Posted - 07/24/24

Wednesday Watchlist: Top Searched Stocks Here are today’s most searched stocks on stocksrunner.com: $AGEN $PYPL $ALKS $PKG $BBSI Keep an eye on these symbols as trading heats up today!

User Image Stocksrunner Posted - 07/24/24

$ALKS Alkermes beats top-line and bottom-line estimates, reaffirming its FY24 outlook. This biopharmaceutical company has a history of delivering, and our attention is now on its future pipeline developments. https://stocksrunner.com/symbol/ALKS

User Image John_Wick1234 Posted - 07/24/24

$ALKS Nice Triple Bottom.

User Image DonCorleone77 Posted - 07/24/24

$ALKS Alkermes reports Q2 non-GAAP EPS 70c, consensus 70c Reports Q2 revenue $399.1M, consensus $393.35M. "Our Q2 results reflect solid execution across our business, delivering double-digit, year-over-year growth for our proprietary commercial product portfolio and robust profitability. We enter the second half of the year in a strong financial position with clear operational priorities to drive the performance of our commercial portfolio and advance our neuroscience development pipeline, including the phase 2 program for ALKS 2680 in narcolepsy type 1 and type 2," said CEO Richard Pops. "As a profitable, smid-cap biotech growth company with multiple commercial products and a development pipeline with significant value potential, we are executing our plan to become a leader in the field of neuroscience."

User Image epsguid Posted - 07/24/24

$ALKS reported earnings of $1.16, consensus was $0.64 via @eWhispers #epsbeat http://eps.sh/d/alks

User Image Stock_Titan Posted - 07/24/24

$ALKS Alkermes plc Reports Second Quarter 2024 Financial Results https://www.stocktitan.net/news/ALKS/alkermes-plc-reports-second-quarter-2024-financial-j3qnjc5gxd9v.html

User Image oregonstonker Posted - 07/19/24

$ALKS Im in on this one... The year over year net profit trends speak for themselves. sorry just had to throw myself out in the sizzle

User Image Stock_Titan Posted - 07/17/24

$ALKS Alkermes to Report Second Quarter Financial Results on July 24, 2024 https://www.stocktitan.net/news/ALKS/alkermes-to-report-second-quarter-financial-results-on-july-24-491ilxrr5lw9.html

User Image DonCorleone77 Posted - 3 months ago

$NBIX $ALKS $INDV Jefferies says Neurocrine, Alkermes not seeing Sublocade-like impact on Medicaid After Indivior (INDV) reduced FY24 guidance due to the removal of automatic Medicaid coverage renewals for Sublocade, Jefferies caught up with both Neurocrine (NBIX) and Alkermes' (ALKS) management teams and notes that neither is seeing a Sublocade-like impact regarding Medicaid claims going into Q2. The firm maintains a Buy rating and $175 price target on Neurocrine shares and a Buy rating and $50 price target on Alkermes.

Analyst Ratings
Cantor Fitzgerald Overweight Sep 16, 24
Cantor Fitzgerald Overweight Jul 25, 24
JP Morgan Neutral Jul 25, 24
Baird Outperform Jul 25, 24
HC Wainwright & Co. Neutral Jul 25, 24
JP Morgan Neutral Jul 15, 24
TD Cowen Buy Jun 17, 24
HC Wainwright & Co. Neutral Jun 4, 24
Cantor Fitzgerald Overweight May 23, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
LAURENCIN CATO T Director Director Jun 07 Sell 31.5 2,800 88,200 7,479 06/07/23
LAURENCIN CATO T Director Director Jun 07 Option 22.97 2,800 64,316 10,279 06/07/23
Nichols Christian Todd SVP, Chief Commercia.. SVP, Chief Commercial Officer May 30 Sell 28.93 27,134 784,987 40,984 05/30/23
Nichols Christian Todd SVP, Chief Commercia.. SVP, Chief Commercial Officer May 30 Option 20.43 19,634 401,123 68,118 05/30/23
Nichols Christian Todd SVP, Chief Commercia.. SVP, Chief Commercial Officer Jun 21 Sell 28.2584 7,474 211,203 21,035 06/21/22
POPS RICHARD F Director and CEO, Al.. Director and CEO, Alkermes plc May 05 Option 16.55 450,000 7,447,500 1,062,046 05/06/22
POPS RICHARD F Director and CEO, Al.. Director and CEO, Alkermes plc May 05 Sell 28.13 347,257 9,768,339 968,299 05/06/22
Cooke Shane Director Director Apr 11 Option 16.55 10,000 165,500 100,478 04/12/22
Cooke Shane Director Director Apr 11 Sell 29.26 10,000 292,600 90,478 04/12/22
Cooke Shane Director Director Apr 04 Option 16.55 10,000 165,500 100,478 04/05/22
Cooke Shane Director Director Apr 04 Sell 28.18 10,000 281,800 90,478 04/05/22
Hopkinson Craig C. EVP R&D, Chief Medic.. EVP R&D, Chief Medical Officer Feb 23 Sell 24.7559 11,983 296,650 17,994 02/24/22
Hopkinson Craig C. EVP R&D, Chief Medic.. EVP R&D, Chief Medical Officer Feb 18 Sell 25.17 2,306 58,042 9,496 02/23/22
ANSTICE DAVID W Director Director Jun 08 Option 14.6 5,000 73,000 78,081 06/08/21
DIXON WENDY L Director Director Apr 20 Option 14.6 25,000 365,000 61,600 04/20/21
DIXON WENDY L Director Director Apr 20 Sell 20 25,000 500,000 36,600 04/20/21
Brown Iain Michael SVP, Chief Financial.. SVP, Chief Financial Officer Apr 20 Option 18.11 35,000 633,850 83,154 04/20/21
Brown Iain Michael SVP, Chief Financial.. SVP, Chief Financial Officer Apr 20 Sell 19.99 35,000 699,650 48,362 04/20/21
DIXON WENDY L Director Director Jan 15 Option 12.62 35,000 441,700 36,600 01/15/21